178 related articles for article (PubMed ID: 15136217)
21. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
[TBL] [Abstract][Full Text] [Related]
22. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
De Bruyne E; Bos TJ; Asosingh K; Vande Broek I; Menu E; Van Valckenborgh E; Atadja P; Coiteux V; Leleu X; Thielemans K; Van Camp B; Vanderkerken K; Van Riet I
Clin Cancer Res; 2008 May; 14(10):2918-26. PubMed ID: 18483358
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
25. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.
Kumar S; Rajkumar SV; Kimlinger T; Greipp PR; Witzig TE
Leukemia; 2005 Aug; 19(8):1466-70. PubMed ID: 15959533
[TBL] [Abstract][Full Text] [Related]
26. [The analysis of prognostic variables in 123 patients with multiple myeloma].
Xu Y; Deng SH; Mai YJ; Li X; Qi PJ; Zhao YZ; Zou DH; Wang YF; Qian LS; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):330-4. PubMed ID: 17877163
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
28. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Lenhoff S; Hjorth M; Westin J; Brinch L; Bäckström B; Carlson K; Christiansen I; Dahl IM; Gimsing P; Hammerström J; Johnsen HE; Juliusson G; Linder O; Mellqvist UH; Nesthus I; Nielsen JL; Tangen JM; Turesson I;
Br J Haematol; 2006 May; 133(4):389-96. PubMed ID: 16643445
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.
Sahara N; Ohnishi K; Ono T; Sugimoto Y; Kobayashi M; Takeshita K; Shigeno K; Nakamura S; Naito K; Tamashima S; Nara K; Tobita T; Takeshita A; Ohno R
Eur J Haematol; 2006 Jul; 77(1):14-8. PubMed ID: 16827882
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.
Johnsen HE; Bøgsted M; Klausen TW; Gimsing P; Schmitz A; Kjaersgaard E; Damgaard T; Voss P; Knudsen LM; Mylin AK; Nielsen JL; Björkstrand B; Gruber A; Lenhoff S; Remes K; Dahl IM; Fogd K; Dybkaer K; ;
Cytometry B Clin Cytom; 2010 Sep; 78(5):338-47. PubMed ID: 20533391
[TBL] [Abstract][Full Text] [Related]
32. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
33. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
35. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
37. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
Efferth T; Fabry U; Osieka R
Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
[TBL] [Abstract][Full Text] [Related]
39. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
